UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):June 27, 2007
MOLECULAR INSIGHT PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
| | | | | |
Massachusetts
(State or Other Jurisdiction
of Incorporation) | | 001-33284
(Commission
File Number) | | 04-0562086
(IRS Employer
Identification No.) |
160 Second Street, Cambridge, Massachusetts 02142
(Address of Principal Executive Offices, Including Zip Code)
(617) 492-5554
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
| | |
| ¨ | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ¨ | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ¨ | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ¨ | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 1.01 Entry into a Material Definitive Agreement.
The Company’s Amended and Restated 2006 Equity Incentive Plan (the “2006 Plan”) was approved by the shareholders of the Company in August 2006 and became effective on February 2, 2007. The 2006 Plan was filed as Exhibit 10.19 to the Company’s Registration Statement on Form S-1 (Registration No. 333-129570), as amended.
On June 27, 2007, the Compensation Committee of the Board of Directors of the Company approved the forms of incentive stock option award agreement and nonqualified stock option award agreement for use under the 2006 Plan. The Company intends to use these forms of agreements from time to time in connection with awards to officers, directors and certain employees.
Forms of incentive stock option award agreement and nonqualified stock option award agreement are filed as Exhibit 10.1 and Exhibit 10.2 respectively to this Current Report on Form 8-K and are incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
| | | |
| | | |
| (d) | | Exhibits. The following exhibit is furnished pursuant to Items 1.01: |
| | | |
| | | 10.1 Form of Incentive Stock Option Award. |
| | | |
| | | 10.2 Form of Nonqualified Stock Option Award. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized, on the 2nd day of July, 2007.
| | | | | |
| | MOLECULAR INSIGHT PHARMACEUTICALS, INC.
| |
| | By: | /s/ David S. Barlow | |
| | | Name: | David S. Barlow | |
| | | Title: | Chairman and Chief Executive Officer | |
Exhibit Index to Current Report on Form 8-K
| | | |
| Exhibit | | |
| Number | | Description |
| | | |
| 10.1 | | Form of Incentive Stock Option Award. |
| | | |
| 10.2 | | Form of Nonqualified Stock Option Award. |
